Hanns Christian Mahler
About
Hanns Christian Mahler is from Basel, Basel, Switzerland. Hanns-Christian works in the following industries: "Pharmaceutical Manufacturing". Hanns-Christian is currently CEO (Chief Enablement Officer) & Board Member at ten23 health, located in Basel & Visp, Switzerland. Hanns-Christian also works as Board Member & Scientific Advisor at Bionter, a job Hanns-Christian has held since Apr 2021. Another title Hanns-Christian currently holds is Editor, Journal of Pharmaceutical Sciences (J.Pharm.Sci.) at Elsevier. In Hanns-Christian's previous role as a CEO at swissfillon AG, Hanns-Christian worked in Visp, Valais, Switzerland until Jan 2023. Prior to joining swissfillon AG, Hanns-Christian was a Head of Drug Product Services at Lonza and held the position of Head of Drug Product Services at Basel Area, Switzerland. Prior to that, Hanns-Christian was a Head Pharmaceutical Development & Supplies at F. Hoffmann-La Roche from Mar 2010 to Aug 2015. Hanns-Christian started working as Head of Pharmaceutical R&D Biologics and Parenterals at Roche in Apr 2005. From Jan 2000 to Jan 2005, Hanns-Christian was Principal Scientist Pharmaceutical Development & CMC Project Manager Erbitux at Merck KGaA.
You can find Hanns Christian Mahler's email at finalscout.com. FinalScout is a professional database with business professional profiles and company profiles.
Hanns Christian Mahler's current jobs
Founder, CEO, Board member/Chairperson of ten23 health group and its affiliates.
Delivery beyond barriers
Hanns Christian Mahler's past jobs
affiliate of ten23 health
Building up and leading the sterile product business at Lonza (development, manufacture, testing for clinical & commercial drug product). - Head Business Unit / G.M. Step-Up Growth Project and P&L responsible, Sterile Drug Product Business - Operative Head, DPS business (DP Pharmaceutical, Process & Packaging and Device Development, Clinical & Commercial DP Manufacturing, Analytical Development & Quality Control, Project management) - Head of PharmSci Innovation - Site Head, Lonza Basel Stücki/Stein
(Pharma Global Technical Operations, Technical Development, Biologics Europe) - Early-Stage Pharmaceutical Development (Biologics, peptides, oligo's, NCE parenterals, ocular dosage forms, vaccines) - Drug delivery - R&D Stability - Preclinical GLP supplies - Late-Stage Pharmaceutical and Processing Development (Biologics, peptides, NCE parenterals) - Primary Packaging Development - Drug Product GMP Clinical Supply (Phase 1-3): liquid vials, lyophilisates, prefilled syringes, cartridges, AI/NSD device/combination product assembly - Scaleup, Transfer to Production, Process Validation, PC/PV, Quality by design (QbD), Launch - Tech Transfer and Established/Commercial Product Support - New Technologies (Research, technology development, implementation) - Department leadership (130+ staff)
(Pharma Research, Technical Sciences) April 2005 - March 2008: Head Formulation R&D Biologics, from April 2008 onwards Heading Pharmaceutical R&D Biologics and Parenterals - Formulation R&D Biologics and small-molecule parenterals - Clinical Supplies (Drug Product) and preclinical supplies (GLP)
Formulation R&D Parenterals (NCE, Biotech), Manufacturing, Upscale, Technical Registration, CMC Project Coordination (Erbitux), Validation, Filing & Approvals